These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 10212757

  • 1. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.
    Chang SC, Fang CT, Hsueh PR, Luh KT, Hsieh WC.
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):299-303. PubMed ID: 10212757
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ.
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [Abstract] [Full Text] [Related]

  • 3. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
    Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW.
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
    Wang FD, Lin ML, Liu CY.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
    [Abstract] [Full Text] [Related]

  • 5. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J, Oguri T, Hiramatsu N, Akiyama K, Koyama T.
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
    Schouten MA, Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
    [Abstract] [Full Text] [Related]

  • 8. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG.
    Drugs; 1996 Aug; 51 Suppl 1():31-7. PubMed ID: 8724814
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
    Speciale A, La Ferla K, Caccamo F, Nicoletti G.
    Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
    Putnam SD, Jones RN, Johnson DM.
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
    [Abstract] [Full Text] [Related]

  • 12. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
    Bouanchaud DH.
    J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF, Booker BM, Ogundele AB, Kelchin P.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
    Tünger A, Aydemir S, Uluer S, Cilli F.
    Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H, Giamarellos-Bourboulis EJ, Grecka P, Chryssouli Z, Giamarellou H.
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [Abstract] [Full Text] [Related]

  • 20. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y, Tsukamoto T, Hirose T, Yokoo A, Hikichi Y, Shigeta S, Takanashi T, Shiraiwa Y, Ogiwara M, Yoshida H, Imafuku Y, Murai M, Watanabe K, Uchida H, Kobayashi Y, Matsuda S, Fujime M, Fujita K, Igari J, Oguri T, Kosakai N, Yamaguchi K, Matsumoto T, Kashitani F, Tanaka M.
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.